Merck Wins Two Suits Against Mylan

WHITEHOUSE STATION, N.J. -- Drugmaker Merck & Co. (MRK) has won two patent infringement lawsuits against a generic drugmaker seeking to make copycat versions of its lucrative cholesterol pills, Zetia and Vytorin.

Merck says U.S. District Judge José Linares in Newark, N.J., ruled Friday against Mylan Pharmaceuticals Inc. ( MYL)

> > Bull or Bear? Vote in Our Poll

Both lawsuits concern the patent for ezetimibe, Zetia's active ingredient and a part of Vytorin, which also includes generic Zocor. That's an older Merck cholesterol pill that works differently.

The judge ruled the patent, which runs until April 2017, is valid, so Mylan cannot make generic versions of the drugs until then.

In the first quarter, Zetia had sales of $614 million and Vytorin dipped to $444 million. Together, they had 2011 sales of $4.3 billion.

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Stocks

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says